Neuronetics Stock Today
| STIM Stock | USD 1.42 0.01 0.70% |
PerformanceWeakest
| Odds Of DistressRisky
|
Neuronetics is selling at 1.42 as of the 27th of December 2025; that is 0.7 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.34. Neuronetics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 12th of January 2023 and ending today, the 27th of December 2025. Click here to learn more.
Business Domain Health Care Equipment & Services | IPO Date 28th of June 2018 | Category Healthcare | Classification Health Care |
Neuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. Neuronetics, Inc. was incorporated in 2001 and is headquartered in Malvern, Pennsylvania. The company has 68.49 M outstanding shares of which 6.71 M shares are at this time shorted by private and institutional investors with about 3.3 trading days to cover. More on Neuronetics
Moving together with Neuronetics Stock
| 0.63 | 300061 | QITIAN Technology | PairCorr |
| 0.71 | 301363 | MeHow Innovative | PairCorr |
| 0.96 | OM | Outset Medical | PairCorr |
Moving against Neuronetics Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Neuronetics Stock Highlights
| CEO President | Keith Sullivan | ||||
| Old Name | ETFS 1x Daily Short Tin ETC | ||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Health Care Equipment & Supplies, Diagnostics & Research, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsNeuronetics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Neuronetics' financial leverage. It provides some insight into what part of Neuronetics' total assets is financed by creditors.
| |||||
Neuronetics (STIM) is traded on NASDAQ Exchange in USA and employs 716 people. Neuronetics is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 97.25 M. Neuronetics conducts business under Health Care Equipment & Supplies sector and is part of Health Care industry. The entity has 68.49 M outstanding shares of which 6.71 M shares are at this time shorted by private and institutional investors with about 3.3 trading days to cover.
Neuronetics currently holds about 73.7 M in cash with (31 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.71, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Neuronetics Probability Of Bankruptcy
Ownership AllocationNeuronetics maintains a total of 68.49 Million outstanding shares. Over half of Neuronetics' outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Neuronetics Ownership Details
Neuronetics Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Goldman Sachs Group Inc | 2025-06-30 | 442.9 K | |
| State Street Corp | 2025-06-30 | 427.9 K | |
| Two Sigma Investments Llc | 2025-06-30 | 367.8 K | |
| Boothbay Fund Management, Llc | 2025-06-30 | 337 K | |
| Ubs Group Ag | 2025-06-30 | 318 K | |
| Northern Trust Corp | 2025-06-30 | 275.4 K | |
| Awm Investment Company Inc | 2025-06-30 | 245.9 K | |
| Hightower Advisors, Llc | 2025-06-30 | 160 K | |
| Two Sigma Advisers, Llc | 2025-06-30 | 157.4 K | |
| Vanguard Group Inc | 2025-06-30 | 2.7 M | |
| Blackrock Inc | 2025-06-30 | 2.2 M |
Neuronetics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Neuronetics market risk premium is the additional return an investor will receive from holding Neuronetics long position in a well-diversified portfolio.
| Mean Deviation | 4.5 | |||
| Standard Deviation | 5.82 | |||
| Variance | 33.92 | |||
| Risk Adjusted Performance | (0.09) |
Neuronetics Stock Against Markets
Neuronetics Corporate Management
| MBA CMA | Chief Officer | Profile | |
| Lisa MetznerRosas | Senior Officer | Profile | |
| Andrew Macan | Gen VP | Profile | |
| Claire Sears | VP Marketing | Profile | |
| Rick Grubbs | Senior Accounts | Profile | |
| Cory Anderson | Senior Clinical | Profile | |
| Kara Thornton | VP Director | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Neuronetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in Neuronetics Stock, please use our How to Invest in Neuronetics guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neuronetics. If investors know Neuronetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neuronetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.83) | Revenue Per Share | Quarterly Revenue Growth 1.013 | Return On Assets | Return On Equity |
The market value of Neuronetics is measured differently than its book value, which is the value of Neuronetics that is recorded on the company's balance sheet. Investors also form their own opinion of Neuronetics' value that differs from its market value or its book value, called intrinsic value, which is Neuronetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neuronetics' market value can be influenced by many factors that don't directly affect Neuronetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neuronetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neuronetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neuronetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.